Evidence check: CYP2C19 in the context of blood sugar

CYP2C19 is primarily known for metabolizing drugs like clopidogrel, proton pump inhibitors, and certain antidepressants. A direct role in blood sugar regulation is not well established. Some studies suggest modest associations with the efficacy of sulfonylureas (diabetes medications) or risk of hypoglycemia, but effect sizes are small and evidence is mixed. Consumer DNA tests reporting CYP2C19 variants can inform about drug metabolism, but not about blood sugar levels per se. Blood glucose homeostasis is mainly driven by insulin, glucagon, diet, and exercise. Genetic factors like TCF7L2 or GCK have stronger, more consistent evidence. Therefore, the evidence for CYP2C19 in the context of blood sugar is weak to moderate. Caution: a CYP2C19 result does not predict diabetes risk or glycemic control. Clinical decisions should rely on established biomarkers and professional medical advice.